Gunst SJ, Herring BP. Altered calcium signaling in colonic smooth muscle of type 1 diabetic mice. Am J Physiol Gastrointest Liver Physiol 302: G66 -G76, 2012. First published October 6, 2011 doi:10.1152/ajpgi.00183.2011.-Seventy-six percent of diabetic patients develop gastrointestinal symptoms, such as constipation. However, the direct effects of diabetes on intestinal smooth muscle are poorly described. This study aimed to identify the role played by smooth muscle in mediating diabetes-induced colonic dysmotility. To induce type 1 diabetes, mice were injected intraperitoneally with low-dose streptozotocin once a day for 5 days. Animals developed hyperglycemia (Ͼ200 mg/dl) 1 wk after the last injection and were euthanized 7-8 wk after the last treatment. Computed tomography demonstrated decreased overall gastrointestinal motility in the diabetic mice. In vitro contractility of colonic smooth muscle rings from diabetic mice was also decreased. Fura-2 ratiometric Ca 2ϩ imaging showed attenuated Ca 2ϩ increases in response to KCl stimulation that were associated with decreased light chain phosphorylation in diabetic mice. The diabetic mice also exhibited elevated basal Ca 2ϩ levels, increased myosin phosphatase targeting subunit 1 expression, and significant changes in expression of Ca 2ϩ handling proteins, as determined by quantitative RT-PCR and Western blotting. Mice that were hyperglycemic for Ͻ1 wk also showed decreased colonic contractile responses that were associated with decreased Ca 2ϩ increases in response to KCl stimulation, although without an elevation in basal Ca 2ϩ levels or a significant change in the expression of Ca 2ϩ signaling molecules. These data demonstrate that type 1 diabetes is associated with decreased depolarization-induced Ca 2ϩ influx in colonic smooth muscle that leads to attenuated myosin light chain phosphorylation and impaired colonic contractility. streptozotocin; colon; voltage-gated calcium channel AS MANY AS 76% OF DIABETIC patients develop gastrointestinal (GI) symptoms, such as dysphagia, vomiting, constipation, diarrhea, or fecal incontinence, that have been linked to poor glycemic control, rather than duration of the disease (3,8). Of these, constipation resulting from impaired colonic motility is the most common symptom and affects ϳ60% of patients (8,24). Animal studies have shown that diabetes can lead to accelerated or delayed GI motility, depending on the animal model used and the specific parts of the GI tract tested. Several studies have used streptozotocin (STZ) to cause specific loss of pancreatic -cells creating type 1 diabetes-like animal models. STZ-induced diabetic rats have been reported to exhibit increased small intestine smooth muscle mass and increased colon contractility (10, 26). The spontaneous contractile activity in STZ-induced diabetic rat colon smooth muscle was increased (12) without a change in intracellular Ca 2ϩ handling (11), while, in the ileum, intracellular Ca 2ϩ handling was decreased (11). Conversely, in STZ-induced diabetic mice, the ...